In that study, we demonstrated that KL co-mutant cells, compared to KRAS mutant cells, show higher HBP activity, KL co-mutant tumor growth, but not KRAS mutant tumor growth, is impaired by the GFPT inhibitor azaserine in both subcutaneous xenograft and autochthonous lung tumor mouse models. This evidence concerns the gene KL and neoplasm.